Menu
Not yet recruiting NCT06838429

PARPi and Ovarian Cancer Survival

— Observational Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum PARP Inhibitor

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, PARP Inhibitor. Basic parameters: 18 years — 80 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Effect of PARP Inhibitors Maintenance Therapy on the Survival Rate of Advanced or Relapsed Epitherlial Ovarian Cancer: an Observational Cohort Study

Overview

With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.

Primary outcome measures

  • Overall Mortality [Time frame: 11 years]

Eligibility criteria

Inclusion criteria

Group 1:

  • Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December 2024.
  • Complete data on first-line treatment and maintenance therapy.
  • Availability of follow-up data.

Group 2:

  • Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December 2024.
  • Disease progression occurring at least 6 months after the completion of the last platinum-based chemotherapy regimen.
  • Complete data on second-line treatment and maintenance therapy.
  • Availability of follow-up data.

Exclusion criteria

Group 1:

  • Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
  • Missing first-line or follow-up data.

Group 2:

  • Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
  • Patients with second relapse.
  • Platinum-resistant patients, such as those who had disease progression during chemotherapy or within 6 months after platinum-based chemotherapy.
  • Missing second-line or follow-up data.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06838429 · PARPi_OC

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗